Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Effect of Pembrolizumab on Quality of Life for Patients With Advanced Lung Cancer

By: Celeste L. Dixon
Posted: Friday, January 26, 2018

Compared with chemotherapy, treatment with pembrolizumab may improve or maintain the health-related quality of life (QOL) of patients with treatment-naive, advanced, programmed cell death ligand 1 (PD-L1)–positive non–small cell lung cancer (NSCLC). These KEYNOTE-24 trial results were reported by a team led by Julie R. Brahmer, MD, of Johns Hopkins Sidney Kimmel Comprehensive Center, Baltimore, in The Lancet Oncology.

Earlier results from the phase III KEYNOTE-24 trial demonstrated longer progression-free survival in this group of about 300 patients who began treatment in 2014 and 2015. These additional findings support the authors’ conclusion that the monoclonal antibody pembrolizumab “might represent a new first-line standard of care for PD-L1–expressing, advanced NSCLC.”

Patient-reported outcomes were an exploratory endpoint of KEYNOTE-24. The patients’ QOL scores were based on responses to the European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 items (QLQ-C30).

Although patients receiving platinum-based chemotherapy had reduced QOL scores after 15 weeks, those receiving pembrolizumab reported better QOL. The mean reduction in QLQ-C30 score was –0.9 for the chemotherapy group; the mean increase for the pembrolizumab group was +6.9.

Dr. Brahmer’s team also evaluated the groups’ “time to deterioration,” a composite result of answers regarding cough, chest pain, and dyspnea in the EORTC QOL Questionnaire–Lung Cancer 13. Here, too, the pembrolizumab group had better results: median not reached for pembrolizumab versus 5.0 months for chemotherapy.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.